Early Career Investigator Grant
(Formerly Liz Tilberis Early Career Award)
Launched in December 2000, the Early Career Investigator Grant is for junior faculty (Assistant Professor level) with a strong commitment to an investigative career in ovarian cancer research. Each grantee will receive a three-year grant of $150,000 per year, for a total of $450,000.
2024 Grant Recipients
-
Sridevi Challa, PhD,
The University of Chicago
Targeting Ribosomal Function to Overcome Chemoresistance in Ovarian Cancer
-
Nicole Marjon, MD, PhD,
University of Colorado - Denver
Reprograming the Ovarian Cancer Immune Microenvironment Via Inhibition of MDSC Recruitment
-
Sarah Gitto, PhD,
University of Pennsylvania
PARP-targeted PET imaging to measure response to PARP inhibitor and immunotherapy in ovarian cancer
-
Melica Brodeur, MD,
Jewish General Hospital
Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer
-
Joshua Doloff, PhD,
Johns Hopkins University
Crystallized drug, biomaterial delivery system for treating ovarian cancer
-
Charles Ishak, PhD,
MD Anderson Cancer Center
Repetitive elements as a therapeutic opportunity to intercept ovarian high grade serous carcinoma
2023 Grant Recipients
-
Xiaowen Hu, PhD,
University of Pennsylvania
Targeting Chromatin Modifiers to Treat Ovarian Cancer
-
Brooke Howitt, MD,
Stanford University
Identifying the Cell of Origin for High- Grade Serous Carcinoma
-
Priyanka Verma, PhD,
Washington University in St. Louis
Role of Chromatin on PARP Inhibitor Responses in BRCA-Mutant Ovarian Cancer
-
Kyle Payne, PhD,
Rutgers University
Mitochondrial Stress Impairs Protective T Cell Immunity in Ovarian Cancer
-
Haider Mahdi, MD,
Magee-Womens Research Institute
Targeting CD47-SIRPa Axis to Overcome Therapy Resistance in Ovarian Cancer
-
Bob McGray, PhD,
Roswell Park Cancer Institute
BiTE-secreting T cells for Adoptive T cell Therapy in Ovarian Cancer
-
Richard Adeyemi, DVM, PhD,
Fred Hutchinson Cancer Research Center
Synthetic Lethality of the Protexin and BRCA Complexes in Ovarian Cancer
2022 Grant Recipients
-
Livnat Jerby,
Stanford University
Targeting multifactorial immune evasion mechanisms in ovarian cancer
-
Haineng Xu, PhD,
University of Pennsylvania
Strategies to Exploit Genetic Alterations in Clear-Cell Ovarian Cancer
-
Jasmine Plummer, PhD,
Cedars-Sinai Medical Center
Chemopreventative Targets in BRCA1 Carrier Models with P53 Lesions (Gail Baird Foundation Research Grant Recipient)
-
Lindsay Brubaker, MD,
University of Colorado - Denver
Targeting Chromobox 2 to Overcome Macrophage-induced Immune Suppression
-
Sammy Ferri-Borgogno, PhD,
MD Anderson Cancer Center
BRCA-deficient Ovarian Cancer and IFITM3: a New Power Couple
-
Maria Victoria Botuyan, PhD,
Mayo Clinic Rochester
Probing How RAD18 and BARD1 Antagonize 53BP1 in HR DNA Repair
-
Chi Lam Au Yeung, PhD,
MD Anderson Cancer Center
Cancer-derived Exosomal miRNAs Modulate Ovarian Tumor Microenvironment
2021 Grant Recipients
-
Ichiko Kinjyo, MD, PhD,
University of New Mexico
A Novel Mechanism for the Immunomodulatory Effects of PARP-inhibitor
-
Arun Kanakkanthara, PhD,
Mayo Clinic
Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer
-
Liya Ding, PhD,
Dana Farber Cancer Institute
Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer
-
Sandra Cascio, PhD,
Magee-Womens Research Institute
EGFL6 as a New Regulator of Myeloid Cell Expansion and Function in HGSOC
2020 Grant Recipients
-
Nidhi Sahni, PhD,
MD Anderson Cancer Center
Systems Approach for PARP-based Novel Combination Therapy in Ovarian Cancer
-
James Duncan, PhD,
Fox Chase Cancer Center
Exploring PROTAC-Mediated Degradation of BRD4 in Ovarian Cancer
-
Mark Eckert, PhD,
University of Chicago
The Fate and Function of Adipocytes in Ovarian Cancer Metastasis
-
Sudipto Ganguly, PhD,
Johns Hopkins University
Characterizing a Novel Checkpoint Axis in High-Grade Serous Ovarian Cancer
-
Brooke Howitt, MD,
Stanford University
Identifying the Cell of Origin for Ovarian High-Grade Serous Carcinoma
-
Sunila Pradeep, PhD,
Medical College of Wisconsin
Epigenetic Causes of Acquired Resistance of Anti-VEGF Therapy
-
Boris Winterhoff, MD,
University of Minnesota Twin Cities
Precision Medicine in Ovarian Cancer: Using Single Cell Analysis
-
Dmitriy Zamarin, MD, PhD,
Memorial Sloan Kettering Cancer Center
Chromatin Remodeling and Immunotherapy in Ovarian Cancer
2019 Grant Recipients
-
Min Soon Cho, PhD,
MD Anderson Cancer Center
The Role of Platelet in the Regulation of Immune Response to Ovarian Cancer
-
Zihua Gong, MD, PhD,
Cleveland Clinic
DNA Repair Pathways as Targets for Therapy-Resistant Ovarian Cancer
-
Xiaowen Hu, PhD,
University of Pennsylvania
Targeting Chromatin Remodeling Complex to Treat Ovarian Cancer
-
Kate Lawrenson, PhD,
Cedars-Sinai Medical Center
Elucidating the Role of SOX17 in HGSOC
-
Elizabeth Stover, MD, PhD,
Dana Farber Cancer Institute
Targeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian Cancer
-
Takemasa Tsuji, PhD,
Roswell Park Comprehensive Cancer Center
Utilization of Tumor-recognizing CD4+T Cells in Cancer Immunotherapy
-
Kris Wood, PhD,
Duke University
Precision Targeting of Altered Mitochondrial States in Ovarian Cancer
2018 Grant Recipients
-
Maria Victoria Botuyan, PhD,
Mayo Clinic
Probing the Antagonistic Roles of 53BP1 and RAD18 in HR DNA Repair
-
Katherine Fuh, MD, PhD,
Washington University in St. Louis
Inhibition of Metastasis in BRCA2-associated Ovarian Cancers
-
Hilary Kenny, PhD,
The University of Chicago
The Role of Mesothelial Cells in Ovarian Cancer Metastasis
-
Chunsheng Li, PhD,
University of Pennsylvania
Imaging Guided Immunotherapy Targeting CD248 for Epithelial Ovarian Cancer
-
Sumegha Mitra, PhD,
Indiana University
UCHL1 Regulates Oncogenic Signaling in Ovarian Cancer
-
Jian Yuan, PhD,
Mayo Clinic
The Role of BRD9-Rad51 Axis in Chemoresistance in Ovarian Cancer
2017 Grant Recipients
-
Alessia Baccarini, PhD,
Mount Sinai School of Medicine
Regulation of the Immune Checkpoint PD-L1 in Ovarian Cancer
-
Ronald Chandler, PhD,
Michigan State University
Integrated Roles of Epigenetics and Cell Signaling in Ovarian Cancer
-
Ilana Chefetz, PhD,
University of Michigan
Drugs Inducing Necroptotic Cell Death As A New Strategy for High Grade Serous Ovarian Cancer
-
Michael Goldberg, PhD,
Dana Farber Cancer Institute
Rational Immunity to Improve Survival Following Standard-of-care Chemo
-
Sunila Pradeep, PhD,
Medical College of Wisconsin
Epigenetic Causes of Acquired Resistance to Anti-VEGF Therapy
-
Boris Winterhoff, MD,
University of Minnesota Twin Cities
Precision Medicine in Ovarian Cancer: Using Single Cell Analysis
2016 Grant Recipients
-
Pradeep Chaluvally-Raghavan, PhD,
Medical College of Wisconsin
Unexpected Role of CLDN11 cdRNA in Ovarian Cancer
-
Alberto Ciccia, PhD,
Columbia University Medical Center
Defining the Molecular Mechanisms of BRCA1-dependent Tumor Suppression
-
Zihua Gong, MD, PhD,
MD Anderson Cancer Center
DNA Repair Pathways as Target for Therapy-Resistant Ovarian Cancer
-
Hui Shen, PhD,
Van Andel Research Institute
An Epigenomic Approach to Delineate Cells of Origin in Early Tumorigenesis
-
Alexandra Snyder Charen, MD,
Memorial Sloan Kettering Cancer Center
Unmasking Ovarian Cancers to Induce Immune Control
-
Sherry Wu, PhD,
MD Anderson Cancer Center
Re-activating Anti-tumor Immunity Using Non-coding RNAs
2015 Grant Recipients
-
Sarah Adams, MD,
University of New Mexico
A Combination Therapy for Hereditary Ovarian Cancer
-
Cesar Castro, MD,
Massachusetts General Hospital
Leveraging DNA-Barcoding for Integrated Profiling of Ovarian Cancer
-
Daniela Dinulescu, PhD,
Brigham and Women’s Hospital
Modeling Serous Ovarian Carcinoma Using Genetic Markers Specific for the Distal Fallopian Tube
-
Yutaka Shoji, PhD,
Michigan State University
ARID1A Regulates ATAD2 in Ovarian Cancer
-
Takemasa Tsuji, PhD,
Roswell Park Cancer Institute
Utilization of Tumor-recognizing CD4+T cells in Cancer Immunotherapy
-
Sarah Walker, PhD,
Dana Farber Cancer Institute
Targeting Transcription Factor Networks for Ovarian Cancer Therapy
-
Kris Wood, PhD,
Duke University
Defining New Combination Therapies for High-grade Serous Ovarian Cancer
2014 Grant Recipients
-
Hiu Wing (Tony) Cheung, PhD,
Medical University of South Carolina
Functional Genomics Approaches to Identify Ovarian Cancer Genes
-
Rachel Grisham, MD,
Memorial Sloan Kettering Cancer Center
Determining the Molecular Drivers of Low-Grade Serous Ovarian Cancer
-
Ryan B. Jensen, PhD,
Yale University
A Cellular Switch to Modulate BRCA2-mediated Tumor Progression
-
Selvendiran Karuppaiyah, PhD,
Ohio State University
New Type of Experimental Drug for Ovarian Cancer
-
Barbara Stulken Norquist, MD,
University of Washington
Molecular Biomarkers to Predict PARP Inhibitor Response in Ovarian Cancer
-
Matthias Stephan, MD, PhD,
Fred Hutchinson Cancer Research Center
In vivo Programming of Ovarian Tumor-reactive T-cells Using Nanoparticles
-
S John Weroha, MD, PhD,
Mayo Clinic
Ovarian Cancer Surrogates to Study Platinum Resistance
2013 Grant Recipients
-
Maria Barbolina, PhD,
University of Illinois - Chicago
Chemokine-Dependent Control of Survival in Ovarian Carcinoma
-
Stephanie Gaillard, MD, PhD,
Duke Cancer Institute
Evaluating ERRalpha as a Novel Therapeutic Target in Ovarian Cancer
-
Michael Goldberg, PhD,
Dana Farber Cancer Institute
siRNA Targeting Immunosuppressive and Oncogenic Pathways in Ovarian Cancer
-
Xin Huang, PhD,
Magee-Womens Research Institute
Noval Strategy of Metabolic Targeting Ovarian Cancer: Focusing on the Tumor Hypoxia Pathway
-
Mythreye Karthikeyan, PhD,
University of South Carolina
Investigating the TGFß Superfamily as Therapeutic Targets in Ovarian Cancer
-
Joyce Liu, MD, MPH,
Dana Farber Cancer Institute
Investigating ErbB3 as a Novel Therapeutic Target in Ovarian Cancer
2012 Grant Recipients
-
Karen Cowden Dahl, PhD,
Indiana University
Investigation of ARID3B Splicing as a Novel Therapeutic Target for Ovarian Cancer
-
Daniela Dinulescu, PhD,
Brigham and Women’s Hospital
Modeling Serous Ovarian Carcinoma Using Genetic Markers Specific for the Distal Fallopian Tube
-
Ivan Garcia-Bassets, PhD,
University of California - San Diego
Targeting the Epigenetic Plasticity of the Platinum Response in Drug-resistant Ovarian Cancer Cells
-
Shannon Hawkins, MD, PhD,
Baylor College of Medicine
The Function of ARID1A in the Transformation of Endometriosis to Ovarian Cancer
-
W. Ruprecht Wiedemeyer, PhD,
Cedars-Sinai Medical Center
Ovarian Cancer Evolution After Targeted Therapy
2011 Grant Recipients
-
Sarah Adams, MD,
University of Pennsylvania
Development of Combination Therapy with PARP-Inhibitors and Immunomodulation for BRCA1-Epithelial Ovarian Cancer
-
Joanna Burdette, PhD,
University of Illinois - Chicago
Identifying Early Events in Ovarian cancer Using a 3-D Model of Ovarian Tissues
-
Analisa DiFeo, PhD,
moun, Mount Sinai School of Medicine and Case Western Reserve University
What is the Relationship Between an miRNA Molecule and Resistance to Chemotherapy?
-
Selvendiran Karuppaiyah, PhD,
Ohio State University
Safe, Targeted, Antitumor Therapeutics (STAT3 Inhibitors) for Ovarian Cancer
-
Ann Klopp, MD, PhD,
MD Anderson Cancer Center
Fat Cells May Be Source of Stem Cells That Promote Ovarian Cancer
-
Bin Zhang, MD, PhD,
University of Texas Health Science Center at San Antonio
Developing Ways to Enhance the Immune System’s Ability to Fight Ovarian Cancer
-
Mary Zhang, MS, PhD,
University South Florida
Understanding Mechanisms that Lead to Resistance to Platinum-based Treatments
2009 Grant Recipients
-
Kathryn Terry, ScD,
Brigham and Women’s Hospital
The Role of Genetics and Environment on Telomere Length in Ovarian Cancer
-
Lin Zhang, MD,
University of Pennsylvania
MicroRNAs, PI-3 kinase, and Ovarian Cancer Stem Cell Differentiation
2008 Grant Recipients
-
Anika Agarwal, MD, MPhil,
Tufts Medical Center
Characterizing a Key Biological Pathway in the Ovarian Cancer Microenvironment
-
Ronald Buckanovich, MD, PhD,
University of Pennsylvania
Tumor Blood Vessels in Ovarian Cancer Development, Diagnosis and for Treatment
-
Jose Conejo-Garcia, MD, PhD,
The Wistar Institute
Reprogramming Immune Cells to Treat Ovarian Cancer
-
Ernst Lengyel, MD, PhD,
University of Chicago
Understanding the Molecular Biology of Metastasis in Ovarian Cancer
-
Monique Spillman, MD, PhD,
University of Colorado - Denver
Determining the Role of Estrogen in Ovarian Cancer
-
Rugang Zhang, PhD,
Fox Chase Cancer Center
Exploiting Natural Cell Behavior to Stop Cancer Cell Growth
2007 Grant Recipients
-
Deborah Altomare, PhD,
University of Central Florida
Clarifying the Molecules Involves in Ovarian Cancer Growth and Progression
-
Stephen L. Rose, MD,
University of Wisconsin-Madison Medical School
Studying the Molecules Involved in Ovarian Cancer Development
2006 Grant Recipients
-
Lin Zhang, MD,
University of Pennsylvania
The Role of PIK3CA in Epithelial Ovarian Cancer
-
Kathryn Terry, ScD,
Brigham and Women’s Hospital
Telomeres and Telomerase in Relation to Ovarian Cancer Risk
-
Douglas A. Levine, MD,
Memorial Sloan Kettering Cancer Center
Method to Determine if a Male Hormone, Naturally Present in Woman, Affects the Risk of Developing Ovarian Cancer
-
Heidi Gray, MD,
University of Washington
Using Antibodies to Detect Early Ovarian Cancer
-
Denise C. Connolly, PhD,
Fox Chase Cancer Center
Developing Mouse Models of Ovarian Cancer
2005 Grant Recipients
-
Andrew Li, MD,
Cedars-Sinai Medical Center
Testing Medications for Other Conditions to Treat Ovarian Cancer
-
Jose Conejo-Garcia, MD, PhD,
Dartmouth Medical School
Vascular Leukocytes as novel anti-tumor therapeutic targets
-
Jeremy Chien, PhD,
Mayo Clinic
How Cell Shape Changes Lead to Metastasis in Ovarian Cancer
2004 Grant Recipients
-
Ernst Lengyel, MD, PhD,
University of Chicago
Role and Regulation of Hepatocyte Growth Factor and c-Met in Ovarian Cancer
-
Oliver Dorigo, MD, PhD,
University of California - Los Angeles
Phenotypic and Molecular Effects if Phosphoinositide 3-Kinase (PI3 Kinase)/Akt Pathway Activation in Mouse Ovary Using Conditional Deletion of Tumor Suppressor Gene PTEN
-
Ronald Buckanovich, MD, PhD,
University of Michigan
Identification and Validation of Clinically Relevant Targets in Ovarian Tumore Vasculature
2003 Grant Recipients
-
Lin Zhang, MD,
University of Pennsylvania
Transgenic Approaches to Study Ovarian Cancer Prevention
-
Susan K. Murphy, PhD,
Duke University Medical Center
How Chemical Alterations to the DNA-but not its Sequence-May Play a Role in Ovarian Cancer
-
Douglas A. Levine, MD,
Memorial Sloan Kettering Cancer Center
Novel Approaches to the Androgen Pathway and Genetic Predisposition to Ovarian Cancer
-
Denise C. Connolly, PhD,
Mayo Clinic
How Cell Shape Changes Lea to Metastasis in Ovarian Cancer
2002 Grant Recipients
-
Jonathan Lancaster, MD,
Moffitt Cancer Center and Research Institute
Defining Genetic Pathways that Underlie Ovarian Carcinogenesis Using Microarray Expressoin Analysis
-
David E. Cohn, MD,
Ohio State University
Targeting Tumor Blood Vessel Growth Factors with Antibodies as a New Ovarian Cancer Treatment
2001 Grant Recipients
-
Rebecca Liu, MD,
University of Michigan
Dysfunctional Apoptosome Activation in Ovarian Cancer: Implications for Pathogenesis, Prognosis, and Chemoresistance
-
Kimberly Kalli, PhD,
Mayo Clinic
Functional Significance of Insulin Receptors in Epithelial Ovarian Cancer: Therapeutic Implications
-
Christina Bandera, MD,
Dana Farber Cancer Institute
The Molecular Basis of Recurrent Ovarian Cancer and Primary Peritoneal Cancer
2000 Grant Recipients
-
Karen H. Lu, MD,
MD Anderson Cancer Center
Understanding the Molecular Differences in Histologic Grades of Ovarian Cancer: Implications for Discovering New Prognostic Markers
-
Christos Patriotis, PhD,
Fox Chase Cancer Center
Molecular Genetic Mechanisms of Ovarian Oncogenesis
-
Robin Farias-Eisner, MD, PhD,
UCLA School of Medicine
O-glycosylation: a Molecular Mechanism for Transciptional Regulation, Cellular Transformation and Nitric Oxide (NO) Mediated Tumoricidal Activity